• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    2/9/24 6:53:14 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FLAG alert in real time by email
    SC 13G/A 1 CalidiBiotherapeuticsInc.txt CALIDI BIOTHERAPEUTICS INC 13GA Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No._2)* (Name of Issuer) Calidi Biotherapeutics, Inc. (formerly known as First Light Acquisition Group Inc.) (Title of Class of Securities) Class A common stock, par value $0.0001 per share (CUSIP Number) 320703101 (Date of Event Which Requires Filing of this Statement) 12/31/2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 320703101 (1) Names of reporting persons Polar Asset Management Partners Inc. (2) Check the appropriate box if a member of a group (see instructions) (a) (b) (3) SEC use only (4) Citizenship or place of organization Ontario, Canada Number of shares beneficially owned by each reporting person with: (5) Sole voting power 2,290,086 (including 2,165,086 shares issuable upon the exercise of warrants) (6) Shared voting power (7) Sole dispositive power 2,290,086 (including 2,165,086 shares issuable upon the exercise of warrants) (8) Shared dispositive power (9) Aggregate amount beneficially owned by each reporting person 2,290,086 (including 2,165,086 shares issuable upon the exercise of warrants) (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 6.1% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Calidi Biotherapeutics, Inc. (formerly known as First Light Acquisition Group Inc.) Item 1(b) Address of issuer's principal executive offices: 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO, CA, 92121 2(a) Name of person filing: This statement is filed by Polar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada, which serves as the investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company ("PMSMF") with respect to the shares directly held by PMSMF. 2(b) Address or principal business office or, if none, residence: 16 York Street, Suite 2900, Toronto, ON, Canada M5J 0E6. 2(c) Citizenship: Canada 2(d) Title of class of securities: Common stock, par value $0.0001 per share 2(e) CUSIP Number: 320703101 Item 3. [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); [x] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: The Reporting Person is an investment fund manager, portfolio manager, exempt market dealer and commodity trading manager registered with the Ontario Securities Commission. Item 4. Ownership as of December 31, 2023 1. Polar Asset Management Partners Inc. (a) Amount beneficially owned: 0 (b) Percent of class: 6.1% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 2,290,086 (including 2,165,086 shares issuable upon the exercise of warrants) (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 2,290,086 (including 2,165,086 shares issuable upon the exercise of warrants) (iv) Shared power to dispose or to direct the disposition of: 0 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Instruction. Dissolution of a group requires a response to this item. Not applicable Item 6. Ownership of More than 5 Percent on Behalf of Another Person. Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 9, 2024 POLAR ASSET MANAGEMENT PARTNERS INC. By: /s/ Andrew Ma Name: Andrew Ma Title: Chief Compliance Officer
    Get the next $FLAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLAG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLAG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

    Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP and intends to enter into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $50 million; proceeds to extend Calidi's cash runway

    9/13/23 5:50:00 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments

    Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP Listed company to be named Calidi Biotherapeutics, Inc. Common stock and warrants approved for listing on the New York Stock Exchange American under the ticker symbols

    9/11/23 4:05:40 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET

    NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE:FLAG) ("FLAG") today announced that it convened and then adjourned, without conducting any other business, its virtual Special Meeting of Stockholders to August 24, 2023 at 10:30 a.m., Eastern time (the "Special Meeting"). The adjourned Special Meeting will be held via the same live webcast at https://www.cstproxy.com/firstlightacquisition/2023. The Special Meeting is being held to consider and vote on, among other things, the business combination transaction between FLAG and Calidi Biotherapeutics, Inc. ("Calidi"), pursuant to an Agreement and Plan of Merger, dated January 9, 203, as amended, by and amo

    8/22/23 11:41:05 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FLAG
    SEC Filings

    View All

    First Light Acquisition Group Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    2/12/24 6:30:32 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by First Light Acquisition Group Inc.

    424B3 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    2/12/24 6:32:40 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    First Light Acquisition Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    2/7/24 1:06:39 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FLAG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zulueta Alfonso G was granted 5,644 shares, increasing direct ownership by 4% to 133,301 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    1/4/24 7:55:27 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stewart Alan R. was granted 7,282 shares, increasing direct ownership by 15% to 54,655 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    1/4/24 7:52:55 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Schoeneck James A was granted 10,625 shares, increasing direct ownership by 62% to 27,872 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    1/4/24 7:51:34 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FLAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    2/14/24 4:02:35 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    2/14/24 6:05:50 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    2/12/24 5:32:10 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care